- Home
- Publications
- Publication Search
- Publication Details
Title
Romosozumab: A Review in Postmenopausal Osteoporosis
Authors
Keywords
-
Journal
DRUGS & AGING
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-09-11
DOI
10.1007/s40266-020-00793-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ANABOLIC THERAPY AND OPTIMAL TREATMENT SEQUENCES FOR PATIENTS WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE
- (2020) Felicia Cosman Endocrine Practice
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS—2020 UPDATE
- (2020) Pauline M. Camacho et al. Endocrine Practice
- Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab
- (2020) S.R. Cummings et al. OSTEOPOROSIS INTERNATIONAL
- Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture
- (2020) James R. Turk et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
- (2019) Pascale Chavassieux et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension
- (2019) Akimitsu Miyauchi et al. Archives of Osteoporosis
- Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome
- (2018) Felicia Cosman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture
- (2018) Chor-Wing Sing et al. JOURNAL OF BONE AND MINERAL RESEARCH
- FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab
- (2018) Felicia Cosman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis
- (2018) Anne Sophie Koldkjær Sølling et al. Therapeutic Advances in Musculoskeletal Disease
- One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study
- (2018) E Michael Lewiecki et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Fracture Prevention with Zoledronate in Older Women with Osteopenia
- (2018) Ian R. Reid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
- (2017) Bente L Langdahl et al. LANCET
- Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
- (2017) Kenneth G. Saag et al. NEW ENGLAND JOURNAL OF MEDICINE
- Wnt Signaling Pathway Inhibitor Sclerostin Inhibits Angiotensin II–Induced Aortic Aneurysm and AtherosclerosisHighlights
- (2016) Smriti Murali Krishna et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis
- (2016) Guido Kranenburg et al. ATHEROSCLEROSIS
- Sclerostin Inhibition in the Management of Osteoporosis
- (2016) Natasha M. Appelman-Dijkstra et al. CALCIFIED TISSUE INTERNATIONAL
- Romosozumab Treatment in Postmenopausal Women with Osteoporosis
- (2016) Felicia Cosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Postmenopausal osteoporosis
- (2016) Richard Eastell et al. Nature Reviews Disease Primers
- Teriparatide Increases Strength of the Peripheral Skeleton in Premenopausal Women With Idiopathic Osteoporosis: A Pilot HR-pQCT Study
- (2014) Kyle K. Nishiyama et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Romosozumab in Postmenopausal Women with Low Bone Mineral Density
- (2014) Michael R. McClung et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study
- (2013) Desmond Padhi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- WNT signaling in bone homeostasis and disease: from human mutations to treatments
- (2013) Roland Baron et al. NATURE MEDICINE
- The role of estrogen and androgen receptors in bone health and disease
- (2013) Stavros C. Manolagas et al. Nature Reviews Endocrinology
- Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis
- (2012) Frederick Wolfe et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study
- (2012) J.-H. Kang et al. OSTEOPOROSIS INTERNATIONAL
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
- (2009) Steven R. Cummings et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment
- (2008) Barbara M Obermayer-Pietsch et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate
- (2008) Paul D. Miller et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis
- (2007) Steven Boonen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now